/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Lyell Immunopharma, Inc Share Price Today: Live Updates & Key Insights

Lyell Immunopharma, Inc share price today is $24.3, up -1.45%. The stock opened at $23.94 against the previous close of $25.14, with an intraday high of $25.07 and low of $23.94.

Lyell Immunopharma, Inc Share Price Chart

style
pb-0

Lyell Immunopharma, Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Lyell Immunopharma, Inc Share Price Performance

$24.3 -0.0145(-1.45%) LYEL at 13 Mar 2026 02:11 PM Biotechnology
Lowest Today 23.94
Highest Today 25.07
Today’s Open 23.94
Prev. Close 25.14
52 Week High 45.00
52 Week Low 7.65
Day’s Range: Low 23.94 High 25.07
52-Week Range: Low 7.65 High 45.00
1 day return -
1 Week return +10.18
1 month return -2.67
3 month return -23.57
6 month return +88.65
1 year return +3986.78
3 year return +1000.88
5 year return +47.0
10 year return -

Lyell Immunopharma, Inc Institutional Holdings

ARCH VENTURE CORP 14.30

MWG Caph Ltd 5.23

MWG Management Ltd. 5.23

Vanguard Group Inc 4.28

Foresite Capital Management IV, LLC 4.15

Orland Properties Ltd 3.91

Almitas Capital LLC 2.99

Vanguard Total Stock Mkt Idx Inv 2.78

Foresite Capital Management V, LLC 2.47

Citadel Advisors Llc 1.76

venBio Partners LLC 1.75

Alphabet Inc 1.52

BlackRock Inc 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.81

HSG Holding Ltd 0.79

Geode Capital Management, LLC 0.68

Millennium Management LLC 0.65

MIC Capital Management UK LLP 0.45

Charles Schwab Investment Management Inc 0.44

RBF LLC 0.39

Schwab US Small-Cap ETF™ 0.36

Fidelity Extended Market Index 0.35

iShares Biotechnology ETF 0.27

Orbimed Advisors, LLC 0.27

Invesco Dorsey Wright SmallCap Momt ETF 0.23

Ikarian Capital, LLC 0.23

Blackrock Extended Mkt Fund CF 0.19

Extended Equity Market Fund K 0.16

Fidelity Total Market Index 0.13

TD Health Sciences - I 0.13

Vanguard Health Care ETF 0.12

SEI Tax-Managed Small/Mid Cap F (SIMT) 0.11

Spartan Extended Market Index Pool F 0.10

Fidelity Series Total Market Index 0.10

Bridgeway Ultra-Small Company Market 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

iShares Nasdaq US Biotech ETF USD Acc 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - NL 0.07

Lyell Immunopharma, Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 3

Sell: 1

Strong Sell: 0

Lyell Immunopharma, Inc Fundamentals

Market Cap 534.07 M

PB Ratio 1.6227

PE Ratio 0.0

Enterprise Value 258.73 M

Total Assets 490.86 M

Volume 95960

Lyell Immunopharma, Inc Company Financials

Annual Revenue FY23:48503000 48.5M, FY22:84683000 84.7M, FY21:10650000 10.7M, FY20:7756000 7.8M, FY19:657000 0.7M

Annual Profit FY23:null 0.0M, FY22:84683000 84.7M, FY21:10650000 10.7M, FY20:7756000 7.8M, FY19:657000 0.7M

Annual Net worth FY23:-190099000 -190.1M, FY22:-4754000 -4.8M, FY21:-285501000 -285.5M, FY20:-198533000 -198.5M, FY19:-121256000 -121.3M

Quarterly Revenue Q3/2025:15000 0.0M, Q2/2025:8000 0.0M, Q1/2025:7000 0.0M, Q3/2024:34000 0.0M, Q2/2024:13000 0.0M

Quarterly Profit Q3/2025:15000 0.0M, Q2/2025:8000 0.0M, Q1/2025:7000 0.0M, Q3/2024:34000 0.0M, Q2/2024:-4888000 -4.9M

Quarterly Net worth Q3/2025:-38846000 -38.8M, Q2/2025:-42684000 -42.7M, Q1/2025:-52195000 -52.2M, Q3/2024:-44583000 -44.6M, Q2/2024:-45809000 -45.8M

About Lyell Immunopharma, Inc & investment objective

Company Information Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 300

Industry Biotechnology

CEO Dr. Lynn Seely M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow